Advertisement


Gunter von Minckwitz, MD: Early Survival Analysis of GeparSixto

2015 San Antonio Breast Cancer Symposium

Advertisement

Gunter von Minckwitz, MD, of the German Breast Group, discusses data from this phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (Abstract S2-05).



Related Videos

Breast Cancer

Hans Wildiers, MD, PhD on the TH3RESA Study: Final OS Results

Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).

Breast Cancer

Matthew J. Ellis, PhD, FRCP: Update on Translational Research

Matthew J. Ellis, PhD, FRCP, of the Baylor College of Medicine, gives his expert perspective on this evolving area of research.

Breast Cancer
Symptom Management

Andrew Seidman, MD, and Hope Rugo, MD, on Reducing Alopecia: FDA Approves New Device

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss the recent approval of a cooling cap to reduce hair loss during chemotherapy.

Breast Cancer

Andrew Seidman, MD, and Norman Wolmark, MD, on NSABP Clinical Trials and Management of Early Breast Cancer

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Norman Wolmark, MD, of Allegheny General Hospital, discuss the landmark trials of NSABP that have led to profound changes in breast cancer treatment. (Abstract ML-1)

Breast Cancer

Patricia Ganz, MD, on Results from NSABP B-35: Patient-Reported Outcomes

Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract S6-04).

Advertisement

Advertisement




Advertisement